1 Min Read
June 28 (Reuters) - Quidel Corp:
* Quidel receives FDA clearance and CLIA waiver for its point-of-care sofia 2 instrument for use with sofia respiratory syncytial virus (RSV) assay Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.